Sugi Predict

Sugi Predict / Compounds / SCHEMBL21273391

SCHEMBL21273391

SCHEMBL21273391

CNCc1ccccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 3/20 0.40
▸ LIPG Q9Y5X9 3/20 0.40
▸ LTA4H P09960 1/20 0.39
▸ CXCR2 P25025 2/20 0.38
▸ SLC6A4 P31645 8/20 0.36
▸ SLC6A2 P23975 6/20 0.36
▸ SLC6A3 Q01959 4/20 0.36
▸ KDM4E B2RXH2 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTR2A P28223 2/20 0.34
▸ IFNAR1 P17181 1/20 0.34
▸ MCL1 Q07820 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ ANPEP P15144 1/20 0.33
▸ LAP3 P28838 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29985266 1.00 LPL (0.40) LPLLIPGLTA4HCXCR2SLC6A4
SCHEMBL14630064 0.83 LPL (0.39) LPLLIPGCXCR2SLC6A4SLC6A2
SCHEMBL13202078 0.80 LPL (0.43) LPLLIPGCXCR2ANPEPLAP3
SCHEMBL3319492 0.80 CXCR2 (0.41) LPLLIPGCXCR2
SCHEMBL19817457 0.80 CXCR2 (0.41) LPLLIPGCXCR2ALDH1A1
SCHEMBL20504832 0.79 SLC6A2 (0.34) LPLLIPGLTA4HCXCR2SLC6A4
SCHEMBL2586990 0.79 LPL (0.42) LPLLIPGCXCR2ANPEPLAP3
SCHEMBL30737822 0.79 LPL (0.42) LPLLIPGCXCR2ANPEPLAP3
SCHEMBL30393353 0.79 LPL (0.42) LPLLIPGCXCR2ANPEPLAP3
SCHEMBL11963741 0.79 LPL (0.42) LPLLIPGCXCR2ANPEPLAP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12419962-B2 Quinazolines, pharmaceutical compositions, and therapeutic applications BIOTHERYX, INC. (US) 2025-09-23 — — US disclosed
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHROEDINGER INC (US) 2024-08-22 — — US disclosed
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-06-20 — — US disclosed
US-20240083857-A1 2-Methyl-Quinazolines Bayer Pharma AG (DE) 2024-03-14 — — US disclosed
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2024-01-25 — — US disclosed
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 — — US disclosed
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 — — US disclosed
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-09-21 — — US disclosed
US-20220235013-A1 2-METHYL-QUINAZOLINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2022-07-28 — — US disclosed
CN-113801114-A Fused bicyclic heteroaryl derivative, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2021-12-17 — — CN disclosed
US-10745388-B2 Indazole compounds and uses thereof INCYTE CORPORATION (US) 2020-08-18 — — US disclosed
US-20190256500-A1 INDAZOLE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12419962-B2 Quinazolines, pharmaceutical compositions, and therapeutic applications RAB1A, SOS1, IQGAP1 LPL 4225/4885LIPG 3026/4885LTA4H 3411/4885
US-10745388-B2 Indazole compounds and uses thereof PDXK, PPIP5K2, PCK1 LPL 1586/4885LIPG 2079/4885LTA4H 1516/4885
US-20240083857-A1 2-Methyl-Quinazolines NRAS, KRAS, KSR2 LPL 4880/4885LIPG 3777/4885LTA4H 4774/4885
US-20230293702-A1 QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS RAB1A, SOS1, IQGAP1 LPL 4225/4885LIPG 3026/4885LTA4H 3411/4885
US-20240197888-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST LPL 2971/4885LIPG 3844/4885LTA4H 4148/4885
US-20240025863-A1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS SOS1, SOS2, SOST LPL 2941/4885LIPG 3831/4885LTA4H 4139/4885
US-20240279221-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE APC, RCC2, CDC37 LPL 3820/4885LIPG 3735/4885LTA4H 3558/4885
US-20220235013-A1 2-METHYL-QUINAZOLINES NRAS, KRAS, KSR2 LPL 4880/4885LIPG 3777/4885LTA4H 4774/4885
US-20190256500-A1 INDAZOLE COMPOUNDS AND USES THEREOF PDXK, PPIP5K2, PCK1 LPL 1586/4885LIPG 2079/4885LTA4H 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.